AveXis Reports Fourth Quarter and Full Year 2017 Financial and Operating Results

Genetics Investing

AveXis (NASDAQ:AVXS), a clinical-stage gene therapy company developing treatments for patients suffering from rare and life-threatening neurological genetic diseases, today reported financial results for the fourth quarter and full year ended December 31, 2017, recent corporate highlights and upcoming milestones. As quoted in the press release: “2017 was marked by significant progress for AveXis across …

AveXis (NASDAQ:AVXS), a clinical-stage gene therapy company developing treatments for patients suffering from rare and life-threatening neurological genetic diseases, today reported financial results for the fourth quarter and full year ended December 31, 2017, recent corporate highlights and upcoming milestones.

As quoted in the press release:

“2017 was marked by significant progress for AveXis across multiple fronts, including alignment with the U.S. Food and Drug Administration (FDA) on our commercial manufacturing process for AVXS-101, publication of Phase 1 results for spinal muscular atrophy (SMA) Type 1 in the New England Journal of Medicine, and the initiation of pivotal SMA Type 1 and Phase 1 SMA Type 2 trials in the United States,” said Sean Nolan, President and Chief Executive Officer of AveXis. “As we continue this momentum into 2018, we look forward to the pre-Biologics License Application (BLA) meeting with the FDA for AVXS-101, as well as to completing enrollment in our ongoing SMA Types 1 and 2 studies, and to expanding our clinical development program into other SMA sub-populations, and programs beyond SMA.”

Click here to read the full press release.

The Conversation (0)
×